AA
RVNC

Apriem Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Apriem Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-400
Closed -$13K – 615
2015
Q2 		$13K Buy
+400
New +$10.3K ﹤0.01% 391

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Apriem Advisors's RVNC Position: Q3 2015 in Review

Apriem Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2015, closing a stake of 400 shares — an estimated $13K sold.

Apriem Advisors first reported a position in RVNC in Q2 2015 and held it in 1 quarter. The position peaked at $13K in Q2 2015. 79 funds tracked by Wall St. Rank hold RVNC as of Q3 2015.

  • Apriem Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Apriem Advisors sold 400 Revance Therapeutics, Inc. shares in Q3 2015, an estimated $13K.
  • Apriem Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Apriem Advisors's Revance Therapeutics, Inc. position peaked at $13K in Q2 2015.
  • 79 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2015.

Based on Apriem Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.